Equities Analysts Set Expectations for OVID FY2026 Earnings

Ovid Therapeutics (NASDAQ:OVID) – HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for Ovid Therapeutics in a report issued on Friday, September 11th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.36) for the year, up from their prior estimate of ($0.41). HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.38) per share. HC Wainwright also issued estimates for Ovid Therapeutics’ Q4 2026 earnings at ($0.08) EPS, Q1 2027 earnings at ($0.08) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.08) EPS and FY2027 earnings at ($0.29) EPS.

Several other brokerages have also recently issued reports on OVID. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ovid Therapeutics in a research note on Friday, July 17th. UBS Group reiterated a “buy” rating on shares of Ovid Therapeutics in a report on Friday. B. Riley Financial reissued a “buy” rating on shares of Ovid Therapeutics in a research report on Tuesday, July 21st. Roth Capital reaffirmed a “buy” rating and set a $8.00 price objective on shares of Ovid Therapeutics in a research report on Thursday, September 3rd. Finally, Oppenheimer increased their target price on Ovid Therapeutics from $7.00 to $9.00 and gave the company an “outperform” rating in a report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $6.00.

Ovid Therapeutics Trading Up 1.9%

OVID opened at $2.74 on Tuesday. Ovid Therapeutics has a 52 week low of $1.12 and a 52 week high of $3.11. The company has a quick ratio of 12.39, a current ratio of 12.39 and a debt-to-equity ratio of 0.05. The business has a fifty day simple moving average of $2.62 and a 200-day simple moving average of $2.50. The firm has a market cap of $535.12 million, a P/E ratio of -8.84 and a beta of 0.24.

Ovid Therapeutics (NASDAQ:OVID) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.04. The firm had revenue of $0.73 million for the quarter, compared to analysts’ expectations of $0.02 million. Ovid Therapeutics had a negative return on equity of 23.64% and a negative net margin of 240.11%.

Hedge Funds Weigh In On Ovid Therapeutics

A number of large investors have recently modified their holdings of the business. Jupiter Topco LLC purchased a new position in Ovid Therapeutics in the 2nd quarter valued at approximately $55,898,000. BlackRock Inc. purchased a new stake in Ovid Therapeutics during the second quarter worth $29,115,000. Janus Henderson Group PLC purchased a new stake in Ovid Therapeutics during the first quarter worth $23,732,000. Affinity Asset Advisors LLC grew its holdings in Ovid Therapeutics by 48.8% in the first quarter. Affinity Asset Advisors LLC now owns 10,636,318 shares of the company’s stock valued at $23,613,000 after purchasing an additional 3,486,318 shares during the last quarter. Finally, ADAR1 Capital Management LLC acquired a new stake in Ovid Therapeutics in the second quarter valued at $19,953,000. 72.24% of the stock is owned by hedge funds and other institutional investors.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines for rare epileptic disorders and other diseases of the brain. The company’s research programs are designed to address significant unmet needs in patients with severe neurological conditions, including developmental and epileptic encephalopathies.

Ovid has developed a pipeline of investigational therapies targeting the underlying biology of epilepsy and related neurological disorders. Its programs have included soticlestat, an investigational treatment studied in rare epilepsies such as Dravet syndrome and Lennox-Gastaut syndrome, as well as earlier-stage compounds aimed at modulating neurotransmission and reducing seizure activity.

Founded in 2014 and headquartered in New York, Ovid has advanced its programs through collaborations with larger pharmaceutical companies, including a collaboration with Takeda Pharmaceutical Company involving soticlestat.